Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entyvio Extended Access Program in Ulcerative Colitis and Crohn's Disease
NCT02743806Phase 4Terminated
- Sponsor
- Takeda
- Start
- Aug 2016
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 4 trial of vedolizumab in ulcerative colitis (UC), Crohn's disease, sponsored by Takeda. Started Aug 2016; status: terminated.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02743806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743806.